In stark contrast, genetic deletion of the sole inhibitory antibody checkpoint FcγRIIB fundamentally enhances in vivo therapeutic activity of cancer cell direct-targeting antibodies, including those specific for CD20, Her2, and EGFR i.e., clinically validated targets in therapy of hematologic malignancy as well as solid cancer (63). The gene discussed is FCGR2B; the disease is cancer.